NASDAQ · BLLN
Healthcare · Medical - Diagnostics & Research
$104.27
Down-$0.13 (-0.12%)
Updated Sep 16, 2026, 2:11 PM
SID Score
5.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BLLN closed at $104.27 after 20 trading sessions, up 18.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $101.74 | $106.04 | $101.47 | $104.27 | 375.58K |
| Sep 14, 2026 | $98.00 | $101.98 | $97.985 | $100.82 | 420.33K |
| Sep 11, 2026 | $99.37 | $100.8291 | $95.225 | $98.77 | 406.06K |
| Sep 10, 2026 | $97.36 | $101.51 | $96.67 | $98.51 | 729.08K |
| Sep 9, 2026 | $97.54 | $102.98 | $96.69 | $99.16 | 559.25K |
| Sep 8, 2026 | $99.24 | $102.37 | $96.1561 | $99.06 | 590.29K |
| Sep 4, 2026 | $97.84 | $100.7151 | $96.1411 | $99.39 | 976.45K |
| Sep 3, 2026 | $96.75 | $99.61 | $94.16 | $99.50 | 639.34K |
| Sep 2, 2026 | $93.19 | $96.75 | $92.775 | $96.15 | 414.91K |
| Sep 1, 2026 | $90.53 | $94.68 | $90.53 | $92.32 | 426.29K |
| Aug 31, 2026 | $92.50 | $93.255 | $89.78 | $90.67 | 450.71K |
| Aug 28, 2026 | $94.90 | $95.90 | $92.58 | $93.24 | 423.16K |
| Aug 27, 2026 | $96.22 | $99.70 | $94.68 | $95.15 | 670.37K |
| Aug 26, 2026 | $98.95 | $100.42 | $94.94 | $96.22 | 505.55K |
| Aug 25, 2026 | $97.00 | $101.25 | $95.87 | $100.075 | 903.07K |
| Aug 24, 2026 | $95.03 | $97.30 | $92.50 | $96.74 | 548.56K |
| Aug 21, 2026 | $95.64 | $97.9041 | $94.35 | $95.03 | 588.73K |
| Aug 20, 2026 | $91.34 | $96.42 | $91.34 | $95.27 | 684.07K |
| Aug 19, 2026 | $89.87 | $94.25 | $89.19 | $91.67 | 529.95K |
| Aug 18, 2026 | $93.12 | $94.315 | $87.96 | $87.99 | 526.44K |
The latest Smart Investors Daily articles mentioning BLLN.
BLLN research
Company profile and research snapshot.
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 2, 2026 | Canaccord Genuity | Buy | — |
| Aug 6, 2026 | JP Morgan | Overweight | — |
| Aug 6, 2026 | BTIG | Buy | — |
| Jun 29, 2026 | Guggenheim | Buy | — |
| May 13, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 2, 2026
BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Wells Fargo 21st Annual Healthcare Conference.
Benzinga · Sep 2, 2026
Canaccord Genuity analyst Kyle Mikson initiates coverage on BillionToOne (NASDAQ:BLLN) with a Buy rating and announces Price Target of $120.
Yahoo · Sep 1, 2026
BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of Northstar Origin™, a new liquid biopsy add-on test for tissue-of-origin prediction, along with the expansion of its Northstar Select® panel from 84 to 102 genes to cover genes that are included in recent and upcoming FDA approvals.
Yahoo · Aug 28, 2026
When a caller asked for the Mad Money host’s take on BillionToOne, Inc. (NASDAQ:BLLN) during the lightning round on August 26, Jim Cramer commented: You know, we did a big piece on this, and we decided, you know, it’s a pretty darn good company. I know it’s expensive, but you know what? Look, genetic diagnostic, […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BLLN.
